IP Library › Granted Patent US 9,534,051
Granted Patent B2
US 9,534,051 · App. 14/462,596 · Granted Jan 3, 2017

Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,534,051
App. No.
14/462,596
Granted
Jan 3, 2017
Kind
B2
Abstract

Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.

Claims (15)

1. A method of inhibiting proliferation in a T cell, the method comprising contacting the T cell with an antigen and an antigen presenting cell (APC) that has been contacted with a crosslinked anti-Immunoglobulin-like transcript 5 (ILT5) antibody or a crosslinked ILT5-binding fragment of the antibody.

2. The method of claim 1 , wherein the level inhibition of the response is proportional to the amount of antibody or fragment with which the APC is contacted.

3. The method of claim 1 , wherein the contacting is done in vitro.

4. The method of claim 1 , wherein the contacting is done in vivo.

5. The method of claim 1 , wherein the T cell is a CD4+ T cell.

6. The method of any one of claims 1 - 4 , wherein the T cell is a CD8+ T cell.

7. The method claim 1 , wherein the anti-ILT5 antibody or ILT5-binding fragment binds human ILT5.

8. The method of claim 1 , wherein the anti-ILT5 antibody or ILT5-binding fragment is a chimeric antibody.

9. The method of claim 1 , wherein the anti-ILT5 antibody or ILT5-binding fragment is a humanized antibody.

10. The method of claim 1 , wherein the anti-ILT5 antibody or ILT5-binding fragment is an ILT5-binding fragment that is a Fab fragment, a F(ab′) 2 fragment, or a scFv fragment.

11. The method of claim 1 wherein the anti-ILT5 antibody or ILT5-binding fragment is an anti-ILT5 antibody.

12. The method of claim 1 wherein the anti-ILT5 antibody or ILT5-binding fragment comprises an IgG4 constant region.

13. The method of claim 1 wherein the anti-ILT5 antibody or ILT5-binding fragment comprises an IgG1 constant region.

14. The method of claim 4 wherein said contacting is done in the body of a subject suffering from autoimmunity.

15. The method of claim 4 wherein said contacting is done in the presence of an anti-CD3 antibody or antigen-binding fragment.

Assignments (1)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →